trending Market Intelligence /marketintelligence/en/news-insights/trending/1nBnGdOvUidzlZM308yn7Q2 content esgSubNav
In This List

Report: Rakuten acquires more than 20% of medical startup Aspyrian

Blog

Using ESG Analysis to Support a Sustainable Future

Video

S&P Capital IQ Pro | Powered by Expert Insights

Blog

Q&A: Streamlining Analytics for TCFD Reporting

Blog

Evergrande and the wider impact: a sentiment analytics based perspective


Report: Rakuten acquires more than 20% of medical startup Aspyrian

Rakuten Inc., a Japan-based online retailer, has acquired more than 20% of the cancer treatment startup Aspyrian Therapeutics Inc., Nikkei Asian Review reported Nov. 27.

Rakuten CEO, founder, President and Chairman Hiroshi Mikitani is already Aspyrian's biggest shareholder, according to the Japanese publication.

The cancer treatment startup plans to test a treatment method called photoimmunotherapy, which uses infrared light to kill cancer cells, in Japan and the United States. Rakuten eventually plans to combine the health-related data collected on its online platform with Aspyrian's treatment business to form a medical service, Nikkei Asian Review reported.